Insider Selling: Arcus Biosciences, Inc. (NYSE:RCUS) CFO Sells 3,594 Shares of Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CFO Robert C. Goeltz II sold 3,594 shares of Arcus Biosciences stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total value of $53,910.00. Following the sale, the chief financial officer now owns 60,138 shares of the company’s stock, valued at approximately $902,070. This trade represents a 5.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Arcus Biosciences Price Performance

Shares of Arcus Biosciences stock opened at $15.06 on Monday. The stock has a market capitalization of $1.38 billion, a P/E ratio of -4.78 and a beta of 0.87. Arcus Biosciences, Inc. has a one year low of $13.52 and a one year high of $20.31. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The business’s 50 day simple moving average is $15.91 and its two-hundred day simple moving average is $16.01.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.00) EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.06. The company had revenue of $48.00 million during the quarter, compared to analyst estimates of $38.95 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The firm’s revenue was up 50.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.94) EPS. Analysts forecast that Arcus Biosciences, Inc. will post -3.2 EPS for the current year.

Wall Street Analyst Weigh In

RCUS has been the subject of a number of research reports. Barclays boosted their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcus Biosciences in a research report on Thursday, October 3rd. Wells Fargo & Company initiated coverage on Arcus Biosciences in a report on Tuesday, October 8th. They issued an “overweight” rating and a $29.00 price objective for the company. HC Wainwright reissued a “neutral” rating and set a $20.00 price objective on shares of Arcus Biosciences in a report on Wednesday, November 6th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $36.00 target price on shares of Arcus Biosciences in a research note on Thursday, November 7th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $34.00.

Institutional Trading of Arcus Biosciences

Large investors have recently modified their holdings of the business. FMR LLC lifted its holdings in Arcus Biosciences by 6.9% in the 3rd quarter. FMR LLC now owns 4,467,557 shares of the company’s stock worth $68,309,000 after buying an additional 286,766 shares during the period. Point72 Asset Management L.P. boosted its holdings in Arcus Biosciences by 32.9% in the third quarter. Point72 Asset Management L.P. now owns 2,437,073 shares of the company’s stock valued at $37,263,000 after acquiring an additional 603,222 shares in the last quarter. Parkman Healthcare Partners LLC boosted its holdings in Arcus Biosciences by 146.9% in the third quarter. Parkman Healthcare Partners LLC now owns 1,025,754 shares of the company’s stock valued at $15,684,000 after acquiring an additional 610,219 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in Arcus Biosciences by 25.1% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 931,048 shares of the company’s stock valued at $14,236,000 after purchasing an additional 186,750 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Arcus Biosciences by 11.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 566,979 shares of the company’s stock worth $8,669,000 after purchasing an additional 59,536 shares during the period. 92.89% of the stock is owned by institutional investors.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.